Clinical Proton MR Spectroscopy in Central Nervous System Disorders.

Détails

ID Serval
serval:BIB_724F9A669091
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Clinical Proton MR Spectroscopy in Central Nervous System Disorders.
Périodique
Radiology
Auteur(s)
Oz G., Alger J.R., Barker P.B., Bartha R., Bizzi A., Boesch C., Bolan P.J., Brindle K.M., Cudalbu C., Dinçer A., Dydak U., Emir U.E., Frahm J., González R.G., Gruber S., Gruetter R., Gupta R.K., Heerschap A., Henning A., Hetherington H.P., Howe F.A., Hüppi P.S., Hurd R.E.
ISSN
1527-1315 (Electronic)
ISSN-L
0033-8419
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
270
Numéro
3
Pages
658-679
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish
Résumé
A large body of published work shows that proton (hydrogen 1 [(1)H]) magnetic resonance (MR) spectroscopy has evolved from a research tool into a clinical neuroimaging modality. Herein, the authors present a summary of brain disorders in which MR spectroscopy has an impact on patient management, together with a critical consideration of common data acquisition and processing procedures. The article documents the impact of (1)H MR spectroscopy in the clinical evaluation of disorders of the central nervous system. The clinical usefulness of (1)H MR spectroscopy has been established for brain neoplasms, neonatal and pediatric disorders (hypoxia-ischemia, inherited metabolic diseases, and traumatic brain injury), demyelinating disorders, and infectious brain lesions. The growing list of disorders for which (1)H MR spectroscopy may contribute to patient management extends to neurodegenerative diseases, epilepsy, and stroke. To facilitate expanded clinical acceptance and standardization of MR spectroscopy methodology, guidelines are provided for data acquisition and analysis, quality assessment, and interpretation. Finally, the authors offer recommendations to expedite the use of robust MR spectroscopy methodology in the clinical setting, including incorporation of technical advances on clinical units. © RSNA, 2014 Online supplemental material is available for this article.
Pubmed
Web of science
Création de la notice
28/02/2014 18:47
Dernière modification de la notice
03/03/2018 18:17
Données d'usage